SCHEDULE: Millennium Entities Disclose 5.2% Stake in BioXcel

Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a passive beneficial ownership of 5.2% in BioXcel Therapeutics, Inc.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, along with Integrated Core Strategies (US) LLC, collectively reported beneficial ownership in BioXcel Therapeutics, Inc.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 1,028,053 shares, representing 5.2% of the class.
• Integrated Core Strategies (US) LLC reported beneficial ownership of 1,026,054 shares, also representing 5.2% of the class.
• The reporting persons share both voting and dispositive power over these shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of BioXcel Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by a prominent investment firm like Millennium Management can be viewed as a moderately positive signal of institutional confidence in BioXcel Therapeutics, though the filing itself is purely factual and does not express sentiment.

Future Outlook

NA

Industry Context

This filing indicates significant institutional interest in BioXcel Therapeutics, a biotechnology company. Large passive stakes by investment firms like Millennium Management can signal confidence in the company's long-term prospects within the pharmaceutical and biotech sectors, though the filing itself does not provide a rationale for the investment.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by Millennium Management as a positive indicator of confidence in BioXcel Therapeutics' value and future prospects.

Key Dates

Recommendation

The filing indicates that Millennium Management and its affiliates have acquired a significant passive stake (5.2%) in BioXcel Therapeutics. While this demonstrates institutional confidence and could be a positive signal for the stock, a Schedule 13G does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The investment is stated to be passive, not for influencing control. Therefore, a 'hold' recommendation is appropriate, acknowledging the institutional interest without suggesting a change in investment thesis based solely on this ownership disclosure.

Keywords

BioXcel Therapeutics, BXCL, Millennium Management, Israel A. Englander, Institutional Ownership, Schedule 13G, Biotechnology, Pharmaceuticals, Equity Stake